CRISPR Therapeutics AG

NASDAQ:CRSP

Biotechnology

Healthcare
$40.19 +2.70%

+$1.43 today

Market cap
$3.90B
Beta
1.70
P/E (TTM)
-9.2
EPS (TTM)
-$5.92
52W Low $43.23High $78.48

Volume 3.97M

Average 1.70M

CRSP Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

CRISPR Therapeutics AGNASDAQ: CRSP

Financing Cash Flow · Q3 FY2026 · quarter ended Sep 2026

Financing cash flow dips below year-ago levels

Q3 FY2026 financing cash flow of $4.45M fell 98.5% year over year, behind the +120.5% change in trailing-twelve-month financing cash flow. Sequentially, it fell 38.0% from the prior quarter. Over 3 fiscal years it compounded at +122.7% a year.

Context

  • Financing cash flow amounted to 12137.5% of revenue in FY2025, up 11189.0 pp from a year earlier.
  • Financing cash flow increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -98.5% toward the trailing-twelve-month pace of +120.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$4.45M-38.0% QoQ
Last fiscal yearDec 2025
$426.03M+28.3% YoY
LTMSep 2026
$719.96M+120.5% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-98.5%——
1 year+28.3%——
3-year CAGR+122.7%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
426.03M USD
Year-over-year change
+28.3%
4-year CAGR
+14.1%

Financing Cash Flow vs competitors

How CRSP compares with its peers on the latest reported figures

  • CRSP's LTM Sep 2026 financing cash flow of $719.96M is the largest of the 7 companies compared; the peer median is $96.46M.
  • Its year-over-year change of +120.5% is the 4th highest of 7, against a peer median of +168.1%.
  • Financing cash flow amounts to 2860.1% of revenue for CRSP, versus a peer median of 116.2%.
CRSP Competitors Peer median
Financing Cash Flow for CRSP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRSPCRISPR Therapeutics AGLTM Sep 2026$719.96M +120.5%+122.7%2860.1%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$165.06M +31.3%-31.7%249.7%
RGNXREGENXBIO Inc.LTM Mar 2026$108.93M +421.9%—124.0%
BEAMBeam Therapeutics Inc.LTM Jun 2026$107.69M -77.5%+62.4%69.0%
DTILPrecision BioSciences, Inc.LTM Mar 2026$85.22M +305.0%+0.1%189.1%
EDITEditas Medicine, Inc.LTM Mar 2026$41.91M -23.0%+215.9%108.3%
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026$17.96M +1731.5%-42.9%12.7%
Peer median (excluding CRSP) $96.46M+168.1%+0.1%116.2%

Competitors are the stored peer set for CRSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income377.66M(650.18M)(153.61M)(366.25M)(581.6M)
Depreciation & Amortization17.95M24.17M19.84M19.26M19.48M
Deferred Income Tax00000
Stock-Based Compensation102.39M97.95M81.03M86.57M72.5M
Change in Working Capital26.86M19.85M(193.59M)156.27M71.88M
Accounts Receivables(161K)305K(200M)175M25M
Inventory(37.51M)0000
Accounts Payables37.51M5.16M(20.25M)044.89M
Other Working Capital27.02M14.38M26.66M(18.73M)1.99M
Other Non-Cash Items14.11M12.47M(14.05M)(38.62M)72.73M
Operating Cash Flow538.97M(495.74M)(260.38M)(142.77M)(345.01M)
Capital Expenditures(81.71M)(37.19M)(9.47M)(1.9M)(914K)
Acquisitions (Net)953.73M221.47M000
Purchases of Investments(1.51B)(1.42B)(1.07B)(1.49B)(1.01B)
Sales of Investments555.6M1.2B1.45B1.21B1.01B
Other Investing Activities(953.73M)(221.47M)(2.5M)0(34M)
Investing Cash Flow(1.04B)(258.66M)374.65M(280.48M)(31.81M)
Debt Repayment00000
Common Stock Issued213.27M970K62.66M300.7M426.03M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities37.68M37.62M031.29M0
Financing Cash Flow250.95M38.59M62.66M331.98M426.03M
Effect of Forex Changes(11K)(80K)656K(21K)95K
Net Change in Cash(245.52M)(715.88M)177.59M(91.29M)49.3M
Free Cash Flow457.27M(532.93M)(269.85M)(144.68M)(345.93M)

CRISPR Therapeutics AG

NASDAQ:CRSP

Intrinsic Alpha fair value

Locked

Current Price

$40.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.